New WEE1 Inhibitor Study Results Will Be Presented
Researchers are set to share interim findings on an experimental treatment for advanced solid tumors this November.
Updated on Sept. 28, 2026 in Cancer
Live Poll
Do you trust that pharmaceutical companies are transparent when reporting results from experimental cancer drug trials?
Aprea Therapeutics will present updated interim results from its Phase 1 clinical trial of the WEE1 inhibitor APR-1051. The findings for the ACESOT-1051 trial will be shared during an oral plenary presentation in November 2026.
Why it matters
This trial evaluates a new precision oncology approach for patients with advanced solid tumors who have limited options. Understanding the safety and preliminary efficacy of these targeted therapies is essential as clinicians explore new ways to manage aggressive cancers.
The ACESOT-1051 Phase 1 trial (NCT06260514) is an early-stage study evaluating the WEE1 inhibitor APR-1051 in patients with advanced solid tumors. These interim results are preliminary findings intended to provide an initial look at the drug's performance in a human population.
The players
Aprea Therapeutics
A clinical-stage precision oncology company focusing on the development of novel cancer therapies.
Timothy A. Yap
A researcher who will present the interim trial findings.
The details
APR-1051 is designed as a WEE1 inhibitor, a class of drugs that target a key protein involved in DNA damage repair and cell cycle regulation. By inhibiting the WEE1 protein, the treatment aims to prevent cancer cells from repairing their DNA, effectively driving the cells into premature division and eventual cell death. This targeted mechanism is intended to disrupt the rapid proliferation characteristic of advanced solid tumor cancers.
Timeline
November 18-20, 2026: The 38th EORTC-NCI-AACR Symposium occurs in Barcelona.
November 20, 2026, 3 p.m. to 3:10 p.m. CET: Timothy A. Yap will present the interim trial findings.
Health Landscape
This development sits within the broader pursuit of WEE1 inhibitors as a specialized class of cancer therapy. It contributes to the evolving landscape of targeted oncology treatments currently being explored alongside established chemotherapy and immunotherapy standards.
These results are preliminary and pertain to an early-phase clinical trial, meaning they do not yet impact current clinical practice or treatment availability. If you are a patient interested in clinical trial participation, you may discuss with your doctor whether a trial matches your health needs.
The takeaway
The upcoming presentation provides an early look at a targeted therapy designed to disrupt DNA repair in cancer cells. Patients and caregivers should view these early-stage results as scientific progress rather than immediate treatment options, and always consult a doctor about trial eligibility.
Further reading
For more on emerging research in oncology, visit our Cancer section.
More information
Review the full study parameters on the ClinicalTrials.gov trial information page.
Source note: This article includes information reported by MyChesCo.
Live Poll
Do you trust that pharmaceutical companies are transparent when reporting results from experimental cancer drug trials?
